Genetic Diversity of Near Genome-Wide Hepatitis C Virus Sequences during Chronic Infection: Evidence for Protein Structural Conservation Over Time by Li, Hui et al.
Genetic Diversity of Near Genome-Wide Hepatitis C Virus
Sequences during Chronic Infection: Evidence for Protein
Structural Conservation Over Time
Hui Li
1, Austin L. Hughes
2, Nazneen Bano
1, Susan McArdle
1, Stephen Livingston
3, Heike Deubner
4,
Brian J. McMahon
3, Lisa Townshend-Bulson
3, Rachel McMahan
5, Hugo R. Rosen
5, David R. Gretch
1,6*
1Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington, United States of America, 2Department of Biological Sciences,
University of South Carolina, Columbia, South Carolina, United States of America, 3Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium,
Anchorage, Alaska, United States of America, 4Department of Pathology, University of Washington Medical Center, Seattle, Washington, United States of America,
5Division of Gastroenterology and Hepatology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, United States of America,
6Department of Medicine, University of Washington Medical Center, Seattle, Washington, United States of America
Abstract
Infection with hepatitis C virus (HCV) is one of the leading causes of chronic hepatitis, liver cirrhosis and end-stage liver
disease worldwide. The genetics of HCV infection in humans and the disease course of chronic hepatitis C are both
remarkably variable. Although the response to interferon treatment is largely dependent on HCV genotypes, whether or not
a relationship exists between HCV genome variability and clinical course of hepatitis C disease still remains unknown. To
more thoroughly understand HCV genome evolution over time in association with disease course, near genome-wide HCV
genomes present in 9 chronically infected participants over 83 total study years were sequenced. Overall, within HCV
genomes, the number of synonymous substitutions per synonymous site (dS) significantly exceeded the number of non-
synonymous substitutions per site (dN). Although both dS and dN significantly increased with duration of chronic infection,
there was a highly significant decrease in dN/dS ratio in HCV genomes over time. These results indicate that purifying
selection acted to conserve viral protein structure despite persistence of high level of nucleotide mutagenesis inherent to
HCV replication. Based on liver biopsy fibrosis scores, HCV genomes from participants with advanced fibrosis had
significantly greater dS values and lower dN/dS ratios compared to participants with mild liver disease. Over time, viral
genomes from participants with mild disease had significantly greater annual changes in dN, along with higher dN/dS ratios,
compared to participants with advanced fibrosis. Yearly amino acid variations in the HCV p7, NS2, NS3 and NS5B genes were
all significantly lower in participants with severe versus mild disease, suggesting possible pathogenic importance of protein
structural conservation for these viral gene products.
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Introduction
Hepatitis C virus (HCV) is a single-strand, positive-sense RNA
virus classified within the Hepacivirus genus of the Flaviviridae family.
Approximately 3 million people in the United States and 170
million people worldwide are infected with HCV [1]. Upon HCV
infection, up to 80% individuals will develop persistent viraemia
and chronic hepatitis, which potentially leads to liver cirrhosis,
hepatocellular carcinoma, end-stage liver disease, and liver failure
[2]. Cofactors such as alcohol intake, obesity, HIV coinfection and
underlying liver-related diseases also accelerate the progression of
hepatitis C to cirrhosis [3]. The standard treatment for patients
with chronic hepatitis C is a combination of ribavirin and
pegylated interferon alpha, which is effective in eradication of
HCV in approximately 50% of patients despite significant side
effects [4].
The ,9.6 kb HCV genome encodes 59 and 39 untranslational
regions, plus a single open reading frame that is subsequently
processed into three structural proteins (Core, E1, and E2) and
seven non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A
and NS5B). As occurs with many other RNA viruses, HCV
exhibits a considerable degree of sequence variation over the
whole genome. Six major genotypes have been described that
share 70–80% nucleotide identity with one another, along with
more than 80 subtypes that share 80–90% nucleotide identities
within these genotypes [5]. In infected individuals, HCV circulates
as a population of closely related yet distinguishable variants with
less than 10% differences at the nucleotide level [6]. The
distribution of the variant population dynamically deviates
through adaptive or neutral evolution [7]. Several regions on the
HCV genome have been extensively studied in association with
therapeutic resistance and/or clinical outcome, including the
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19562hypervariable region 1 (HVR1) of E2 [8,9,10], the alpha
interferon sensitivity determining region of NS5A [11,12], and
the RNA polymerase of NS5B [13]. Although genetic variation of
individual viral protein domains may be highly significant between
patient groups, multi-domain and whole genome analyses are
needed to facilitate understanding of the role viral diversification
plays with respect to underlying disease mechanisms [14].
The present report describes genetic analysis of near genome-
wide HCV genomes isolated from 9 chronically infected
participants recruited into the well-characterized Alaska Native
cohort [15]. All 9 participants were infected with HCV genotype
1, and had liver biopsies to document progression or stability of
hepatic fibrosis. The median follow up interval post-primary
infection was 23 years, and the interval between specimens ranged
from 5–21 years. HCV whole genome evolution was compared
according to estimated years of infection and disease progression,
making this the first population-based, longitudinal study of
genome-wide HCV genome evolution during chronic infection
and disease.
Materials and Methods
Ethics Statement
The study group was comprised of 9 participants from the
Alaska Native cohort as described previously [15]. All participants
gave written informed consent in accordance with the Institutional
Review Board (IRB) requirements by the Alaska Area IRB, the
Centers for Disease Control and Prevention, and the University of
Washington. All three IRBs specifically approved this study (Text
S1).
Patients and serum specimens
All participants were chronically infected with HCV genotype 1,
negative of HIV and HBV coinfections, and naı ¨ve to interferon or
ribavirin treatment. The participants were all therapy naı ¨ve
because they either did not meet the criteria for treatment outlined
in the AASLD Practice Guidelines (mile disease), or they had a
treatment contraindication (e.g., severe depression), or they chose
not to be treated due to drug toxicity concerns. Patient interview
information was used to estimate the years of HCV infection and
the risk exposure categories (intravenous drug use, before-1992
blood transfusion, or others). Phlebotomy was scheduled every 3–6
months to monitor the hepatic aminotransferase activities [16,17],
and serum specimens were collected at selected time points and
stored at 230uC for future analysis. HCV viral RNA levels were
determined by branched DNA assay (Bayer Corporation, Tarry-
town, NY) and/or quantitative PCR (Roche Diagnostic Systems,
Branchburg, NY) at the University of Washington. HCV genotype
was determined by restriction fragment length polymorphism
analysis of the 59-UTR region and confirmed by probe
hybridization of the Core/E1 region [18,19]. Disease progression
was inferred from liver biopsies (in average 2 biopsies per patient)
that were evaluated by the study pathologist (HD) at the University
of Washington, who was blinded to demographic and clinical data,
according to the Ishak and Knodell scoring system [20,21].
Viral RNA extraction and sequencing
Viral RNA was extracted from 140 mL serum using the
QIAamp viral RNA Mini Kit (QIAGEN Inc., Valencia, CA)
and reverse transcribed with the Superscript III First-Strand
Synthesis System and random hexamers (Invitrogen Corp.,
Carlsbad, CA). Amplification of the near genome-wide HCV
genome was performed with 5–8 PCRs using the Platinum Taq
DNA Polymerase High Fidelity (Invitrogen Corp., Carlsbad, CA)
and multiple sets of primers (Table S1) as illustrated in Figure 1.
The PCR recycling conditions were as follows: 94uC for 2 min,
followed by 35 cycles of 94uC for 30 s, 55uC for 30s, 68uC for
1 min/kb, and a final extension of 68uC for 10 min. The PCR
products were further cloned using the TOPO TA cloning kit
(Invitrogen Corp., Carlsbad, CA), and three colonies were picked
for bidirectional sequencing using the PCR primers and additional
internal primers (Table S2). The sequences were aligned using the
MacVector software (version 9.5, MacVector Inc., Cary, NC) for
each amplified fragment, with the primer sequences removed.
Sequences generated in this study have been deposited in
GenBank under accession numbers HQ113464 through
Figure 1. Strategies used to amplify the near genome-wide HCV genome from 9 participants. The top bar illustrates the HCV genomic
organization with 10 encoded proteins (Core to NS5B) flanked by the 59 and 39 UTRs. Lines below represent the overlapping fragments amplified by
reverse transcription PCR for each participant (PCR primers listed in Table S1). The nucleotide numbering is based on the sequence of HCV H77 strain
(Genbank assession no. NC_004102).
doi:10.1371/journal.pone.0019562.g001
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derived amino acid sequences of the Core region were constructed
and included in Figure S1.
Diversity and entropy analysis
The number of synonymous substitutions per synonymous site
(dS) and the number of non-synonymous substitutions per non-
synonymous (dN) site were estimated using the MEGA and SNAP
program (http://www.hiv.lanl.gov) [22] based on the Nei and
Gojobori’s method [23]. In preliminary analyses, the methods of
Li [24] and Yang and Nielsen [25] yielded essentially identical
results, as expected because the number of substitutions per site
was low in this case [26]. The resulting values were used to
compute the mean of all pairwise synonymous substitution values
(synonymous nucleotide diversity; pS) and the mean of all pairwise
non-synonymous substitution values (non-synonymous nucleotide
diversity; pN). The Shannon entropy per site was determined from
the deduced amino acid sequences of each amplified fragment and
each viral gene using the Entropy program on the Los Alamos
National Laboratories website (http://hcv.lanl.gov/content/
sequence/ENTROPY/entropy_one.html) [27].
Statistical tests
Since each of these amplified fragments was sampled separately
from each patient at each time point, they were treated as
independent samples for purposes of statistical analyses. The
Kruskal-Wallis and Mann-Whitney tests were used to compare
median values of pS, pN, pN/pS, and the Shannon entropy across
categories of patients. The Spearman’s correlation coefficient (r)
was calculated to determine the relationship between measures of
sequence diversity and the estimated year of infection. P-values of
less than 0.05 were considered to be statistically significant. The
statistical tests were performed using the PASW Statistics program
18.0 (SPSS Inc., Chicago, IL).
Results
Sample characteristics
The characteristics of the nine patients included in the study are
summarized in Table 1. Two serum specimens from each
participant were analyzed by near genome-wide sequencing, with
an interval between the early and late collections ranging from 5–
21 years (median=7 years, sum=83 years). The early collections
were at 2–32 years after the initial year of infection (median=13
years), while the late collections were at 13–38 years after the
initial year of infection (median=23 years). All participants were
infected with HCV genotype 1 (8 genotype 1a and 1 genotype 1b),
with mixed-infection or super-infection ruled out by probe
hybridization of the Core/E1 region [19]. HCV RNA level was
estimated as the range of all the documented RNA levels for each
participant (n=3–9) over 2–3 decades, from the initial date of
patient enrollment to the year of the late serum collection. The
participant 1 showed the greatest variation of RNA levels
(log10 IU/ml=4.7–7.3) among the included participants during
chronic infection. Eight of the nine participants underwent at least
one liver biopsy on, or in the case of some participants with mild
disease, after the year of serum collection. Knodell fibrosis stage 0–
1 was considered as the indicator of mild liver disease, and Knodell
fibrosis stages 3–4 were considered as severe liver disease. The
hepatic aminotransferase levels (aspartate aminotransferase, AST;
alanine aminotransferase, ALT; alpha-fetoprotein, AFP) were
estimated as the means of the documented serial aminotransferase
levels (n=1–8) for each participant at the year of serum collection.
The AST/ALT ratio was slightly above 1 at the early time point
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PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19562for the participant 4 (fibrosis stage 0) and at the late time point for
the participants 3 (fibrosis stage 3), 4 (fibrosis stage 0–1) and 8
(fibrosis stage 1). The highest AST/ALT ratio was observed at the
early time point for the participant 8 (fibrosis stage 1; AST/
ALT=2.1) with ALT below the normal level (ALT=32 U/L).
The AFP level was above 8 at the early time point for the
participants 1 (fibrosis stage 4) and 3 (fibrosis stage 1) and at the
late time point for the participant 3 (fibrosis stage 3).
Cross-sectional genome-wide diversity increased during
chronic infection
Median pS (0.0317) was significantly greater than median pN
(0.0052) over the near genome-wide HCV genome (p,0.001).
Thus, purifying selection predominated in the regions of the
genome analyzed. When the data were plotted according to the
estimated years after infection, significant differences of the
distribution of pS, pN and pN/pS were found among the four
categories of 2–10 years, 11–20 years, 21–30 years and 31–38
years after infection (p,0.001 for pS, p=0.021 for pN, and
p=0.006 for pN/pS respectively, Figure 2). pS and pN both
increased over the decades during chronic infection, with a
significant correlation to the estimated year of infection (r=0.556
and p,0.001 for pS, r=0.268 and p=0.008 for pN). The median
pN/pS differed significantly among the four categories, with the
highest value (0.266) occurring at 2–10 years after infection, an
intermediate value (0.203) at 11–20 years after infection, and the
lowest values at 21–30 and 31–38 years after infection (0.096 and
0.166 respectively) (Figure 2C). In individual comparisons, the
median pN/pS at 2–10 years after infection differed significantly
from that at 31–38 years after infection (p=0.034) and from that
at 21–38 years after infection (p=0.002). The decreased pN/pS
ratio was negatively correlated to the estimated year of infection
with a correlation coefficient of 20.300 at statistical significance
(p=0.003; Figure 2D).
Cross-sectional genome-wide diversity associated with
disease status
Fourteen out of the eighteen specimens were matched with a
fibrosis stage (0–4) and a disease status (mild or severe) at the
corresponding time point. Figure 3 shows the comparisons of pS,
pN and pN/pS between the specimens from the mild or severe cases
(n=10 and n=4 for mild and severe, respectively). The median pS
in specimens from the mild cases was significantly lower than that
from the severe cases (p=0.006, Figure 3A), while the median pN
did not differ significantly between the two groups (Figure 3B).
The pN/pS ratio showed a wide range of variations in the group of
mild cases, with a median value significantly greater than that
from the severe cases (0.211 and 0.096 for mild and severe
respectively, p=0.003).
Six out of the nine patients had fibrosis stages available at both
early and late serum collections. Figure 4 shows the comparisons
of pS, pN and pN/pS between the early and late time points
according to the changes of disease status (4 participants with
consistent mild disease, 1 participant with conversion from mild to
severe disease, 1 participant with consistent severe disease). pS and
pN decreased in the participants with severe disease outcomes
(mild-severe or severe-severe) and slightly increased in the
participants with consistent mild disease, although the differences
between early and late time points did not reach statistical
significance (Figures 4A and 4B). The values of pN/pS were lower
in the participants with severe outcomes, with the lowest mean
value (0.096) at the late time point from the participant with mild
Figure 2. Nucleotide diversity compared according to the estimated year of HCV infection. The value of each amplified fragment
covering HCV genome was considered as an independent data point. Panel A, synonymous nucleotide diversity (pS). The distribution of pS differed
significantly across the estimated decades of infection (p,0.001). Panel B, non-synonymous nucleotide diversity (pN). The distribution of pN differed
significantly across the estimated decades of infection (p=0.021). Panel C, pN/pS ratio. The distribution of pN/pS ratio differed significantly across the
estimated decades of infection (p=0.006). Panel D, pN/pS ratio. The pN/pS ratio was significantly negatively correlated to the estimated year of HCV
infection (r=20.300, p=0.003).
doi:10.1371/journal.pone.0019562.g002
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early and late time points were not statistically significant, which
was not surprising given the limited sample size.
Longitudinal genome-wide divergence associated with
disease status
Genome-wide divergence (dS, dN, and dN/dS ratio) was calculated
between the sequences at early and late time points for the six
participants with fibrosis stages available at both serum collections
(4 participants with consistent mild disease, 1 participant with
conversion from mild to severe disease, 1 participant with
consistent severe disease). For all three categories, the median dS
between early and late specimens was significantly greater than the
median dN (p,0.001 for the mild-mild cases, p=0.002 for the
mild-severe case, and p=0.008 for the severe-severe case
respectively, Figures 5A and 5B). Thus there was no evidence of
positive selection favoring amino acid changes. Three participants
(2, 4 and 7) were known as HLA-A2 positive, and nucleotide
substitutions were tested for the specific CD8+ T cell epitopes
presented by HLA-A2 molecules. The median dS was significantly
greater than the median dN in the epitope region (data not shown),
providing no evidence of positive selection favoring amino acid
changes in the specific CD8+ T cell epitopes.
Overall, the distribution of nucleotide divergence (dS and dN)
between the early and late time points did not differ significantly
among the categories of disease status (Figures 5A and 5B). In
comparison of the rate of nucleotide divergence (dS/year and dN/
year, Figures 5C and 5D), the median of dN/year was significantly
greater in the mild-mild cases than that in the mild-severe case
(p=0.008) or that in the two cases with severe outcomes
(p=0.002). The highest median of dN/dS ratio was found in the
mild-mild cases (0.182), which was significantly greater than that
in the mild-severe case (0.080, p=0.003) and that in the two cases
with severe outcomes (0.090, p=0.011) (Figure 5E).
Figure 3. Nucleotide diversity compared according to disease
status. The value of each amplified fragment covering HCV genome
was considered as an independent data point. Panel A, synonymous
nucleotide diversity (pS). The distribution of pS differed significantly
between the mild and severe groups (p=0.006). Panel B, non-
synonymous nucleotide diversity (pN). No significant difference of pN
was found between the mild and severe groups. Panel C, pN/pS ratio.
The distribution of pN/pS differed significantly between the mild and
severe groups (p=0.003).
doi:10.1371/journal.pone.0019562.g003
Figure 4. Nucleotide diversity compared between the early and
late time points. The value of each amplified fragment covering HCV
genome was considered as an independent data point. Panel A,
synonymous nucleotide diversity (pS). Panel B, non-synonymous
nucleotide diversity (pN). Panel C, pN/pS ratio. None of the comparisons
showed significant difference between the early and late time points for
the categories of participants with consistent mild, mild to severe, and
consistent severe disease.
doi:10.1371/journal.pone.0019562.g004
Genetic Diversity of Hepatitis C Virus
PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19562Figure 5. Nucleotide divergence compared according to disease status. The value of each amplified fragment covering HCV genome was
considered as an independent data point. Panel A, synonymous nucleotide divergence (dS). Panel B, non-synonymous nucleotide divergence (dN).
Panel C, synonymous nucleotide divergence per year (dS/year). Panel D, non-synonymous nucleotide divergence per year (dN/year). A significant
difference of dN/year was found between the participants with consistent mild disease and those with mild to severe disease (p=0.008). Panel E, dN/
dS ratio. A significant difference of dN/dS ratio was found between the participants with consistent mild disease and those with mild to severe disease
(p=0.003).
doi:10.1371/journal.pone.0019562.g005
Figure 6. Intra-time-point Shannon entropy of individual genes. The Shannon entropy was calculated at single time point based on the
amino acid sequences of individual genes. Panel A, the intra-time-point Shannon entropy of each gene compared according to the estimated year of
infection. A significant correlation between the Shannon entropy and the estimated year of infection was found for E2, NS2, and NS5A genes. Panel B,
the intra-time-point Shannon entropy of each gene compared according to the mild and severe disease status. No significant difference was found
for the genes between the two disease groups.
doi:10.1371/journal.pone.0019562.g006
Genetic Diversity of Hepatitis C Virus
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19562Genome-wide and gene-specific amino acid variation
The Shannon entropy per site was determined from the
deduced amino acid sequences of the open reading frame of each
amplified fragment as an indicator of the genome-wide amino acid
variation. The intra-time-point Shannon entropy of amplified
fragments differed at borderline significance among the estimated
decades of infection (p=0.051) and increased in significant
association with the estimated year of infection (r=0.224 and
p=0.025) (data not shown). When plotted according to disease
status, no significant difference of the intra-time-point Shannon
entropy was found between the mild and severe groups (data not
shown). Similarly, no significant difference of the inter-time-point
Shannon entropy was found between the cases with consistent
mild disease and those with severe outcomes (data not shown).
To analyze gene-specific amino acid variation, the Shannon
entropy per site was determined for each individual gene. The
envelope gene E2 displayed the highest values of the intra-time-
point Shannon entropy, which were significant different from the
values of the other genes (p,0.001). When plotted according to
duration of infection, the values of intra-time-point Shannon
entropy of three genes (E2, NS2 and NS5A) showed significant
correlation to the estimated year of infection (r=0.483 and
p=0.042 for E2, r=0.485 and p=0.049 for NS2, and r=0.483
and p=0.042 for NS5A, respectively, Figure 6A). When plotted
according to disease status, no difference of the intra-time-point
Shannon entropy was found between the mild and severe cases for
the individual genes (Figure 6B).
The values of inter-time-point Shannon entropy were plotted in
Figure 7 according to the disease outcomes (consistent mild disease
vs. severe disease). Although the inter-time-point Shannon entropy
did not differ significantly between the two groups, the yearly
change of the inter-time-point Shannon entropy of four nonstruc-
tural genes were significantly higher in the cases with consistent
mild disease than those with severe outcomes (p=0.050 for p7,
p=0.050 for NS2, p=0.032 for NS3, and p=0.034 for NS5B,
respectively, Figure 7B).
Discussion
Persistence of viremia with diversification of viral genomes is a
hallmark of chronic HCV infection [9], while insidious course with
variable presentation and progression is a hallmark of the
associated hepatitis C disease [3]. Immunity appears to play a
major role in control of HCV in the acute phase, as subjects who
resolve acute HCV infection have more robust and broader
specificity T cell responses compared to subjects unable to resolve
acute infection [28]. In the chimpanzee model, elegant immune
depletion studies have confirmed the role of T cells immunity in
control of acute hepatitis C [29]. Viral mutational escape from
immune pressure is known to occur, and is considered a major
mechanism of HCV persistence [30,31]. More recent research has
also implicated two additional mechanisms of HCV persistence:
escape from innate immunity via inhibitory action of viral
products on host signaling [32], and exhaustion of virus-specific
adaptive immune responses [33,34,35], which occurs during the
early, post-acute phase of infection, and extends into the chronic
phase of infection, and in theory, may reduce selection.
The role immune escape plays in HCV persistence during the
chronic phase of infection is less clear, as are effects of immune
exhaustion on HCV chronic persistence. The role of immunity in
pressuring HCV during chronic hepatitis C, and in potentially
causing HCV-associated liver injury, is an extremely important
question, which greatly influences therapeutic vaccine develop-
ment. Historically, the immunopathogenesis theory [36], which
believes HCV-specific immunity causes the vast majority of liver
Figure 7. Inter-time-point Shannon entropy of individual genes. The Shannon entropy was calculated between the early and late time points
based on the amino acid sequences of individual genes. Panel A, the inter-time-point Shannon entropy of each gene compared between the
participants with mild or severe outcomes. No significant difference was found for the genes between the two disease groups. Panel B, yearly change
of the inter-time-point Shannon entropy compared between the participants with mild or severe outcomes. Significant differences were found for
the genes of p7, NS2, NS3, and NS5B between the two disease groups.
doi:10.1371/journal.pone.0019562.g007
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One way to estimate host pressure on HCV during the chronic
phase of infection is via sequencing of viral genomes over time,
and analyzing mutation patterns. The synonymous mutation
frequency (dS) generally reflects viral replication efficiency, while
non-synonymous mutations (dN) generally reflect effects of
selection. dN/dS ratios greater than 1 reflect positive selection
against virus (i.e., under immune pressure), while dN/dS ratios
lower than 1 provide an index of purifying selection: the lower the
dN/dS ratio, the stronger the purifying selection.
Toward the objective of characterizing HCV evolution during
the natural disease course in humans, the present study derived
near genome-wide sequences of HCV genomes that circulated
over time in 9 chronically infected research subjects, all of whom
were monoinfected with HCV genotype 1. This is the first long-
term, population-based study of genome-wide viral diversity
during chronic HCV infection, with all participants recruited
from a well-characterized Alaska Native cohort, with specimens
and clinical information archived for as long as 3 decades [9,15].
The treatment naı ¨ve history of the 9 participants allowed
investigation of the association between HCV diversity and
disease development during the natural course of chronic
infection, and to make inferences regarding positive versus neutral
selection during virus evolution.
Examination of genome-wide nucleotide diversity showed an
excess of synonymous substitutions per synonymous site over non-
synonymous substitutions per non-synonymous site in the coding
regions, a pattern seen in the analysis of both intra-time-point
comparison and divergence between the early and late time points.
The predominance of synonymous substitutions suggested that
these sequences were subjected to strong purifying selection, acting
to eliminate non-synonymous mutations. This pattern is opposite
of what one would expect if immune pressure were a prime
influence on evolution, in which case non-synonymous mutations
would be favored. Rather, this observation supports the hypothesis
of the neutral theory of molecular evolution, where purifying
selection is ubiquitous in eliminating deleterious mutations,
whether they be non-synonymous mutations resulting in amino
acid changes, or synonymous mutations altering critical RNA
secondary structure, for example [37]. The same pattern of
purifying selection was seen even in HLA-A2 epitopes. Thus,
although escape from CD8+ T cell recognition is recognized as a
persistence mechanism during acute infection [30], the earliest
samples analyzed here were generally taken several years after
infection, when escape mutations likely have occurred and become
fixed in the viral population infecting a given host [30].
One model to explain the cumulative data on HCV genetics
and immunity is that, for chronic HCV infection to occur, virus
must first survive pressure during the acute phase, either by
mutation, or inhibition of critical intracellular signaling, or T cell
exhaustion, or some combination. Later, during the chronic phase,
profound immune dysfunction could result in purifying selection of
HCV, with predominant synonymous mutations. However, non-
synonymous mutations not eliminated by purifying selection might
result in pathogenic viral variants that accelerate the progression of
disease. An example of how this might work is provided by the
studies of Pavio and colleagues [38], where HCV core variants
isolated from hepatocellular carcinoma cells differed, in a highly
significant fashion, in ability to modulate the TGFbeta response
pathway, which is critical for maintenance of cell differentiation,
compared to HCV core isolated from adjacent, non-cancerous
liver. The molecular mechanism involved inhibition of the DNA-
binding activity of the Smad3/4 transcription factor complex,
through a direct interaction between the central domain (amino
acids 59–126) of tumor-derived core and the MH1 DNA-binding
domain of Smad3, thus preventing its binding to DNA, and
presumably promoting cell transformation by providing, to
clonally expanding cells, resistance to TGF-beta antiproliferative
effects. More experiments addressing frequency and functional
significance of natural variation in HCV proteins are clearly
needed.
In the present study, purifying selection persisted during
chronic infection, as indicated by the significant negative
correlation between the dN/dS ratio and the estimated year of
infection. When comparing HCV genetics between persons with
mild and severe disease, the efficiency of purifying selection was
significantly greater in severe compared to mild disease cases,
with a lower median dN/dS ratio, and a higher median dS. The
participants with severe disease also showed significantly lower
dN/dS ratios when comparing the early and late time points,
compared to participants with consistent mild disease. Despite the
obvious shortcomings of small sample size, the present genetic
study found fewer imprints of adoptive, cellular immune pressure
(non-synonymous mutations) in persons with severe compared to
mild disease, and one could not conclude, from the data, that
cellular immunity is the driving force of hepatitis C disease, as the
leading model presumes. In fact, it has recently been determined,
in both cell culture [39], and a small animal model [40], that
HCV can cause injury and death to hepatocytes, in the absence
of cellular immunity. The significant increases in dS with severe
disease, may have been allowed by immune exhaustion, and
might be due to enhanced viral generation, but might also be
explained by increased virus stability due to RNA secondary
structure advantage, for example. Further studies are needed to
test these possibilities.
The present data hint that immune pressure may have been
greatest in mild disease (this is presently under study), and thus
might be one reason for lower efficiency of purifying selection in
mild disease cases. The viral species are expected to accumulate
more deleterious non-synonymous mutations and as a result, to
show greater amino acid variation. One measure of such amino
acid variation is the Shannon entropy, which is a quantitative
measure of sequence dissimilarity that incorporates both the
frequencies and the number of variation [8,41]. In this study, the
genome-wide Shannon entropy is significantly correlated to the
estimated year of infection and increased gradually over decades,
suggesting enhanced amino acid polymorphism due to accumu-
lated non-synonymous mutations. Analysis of individual genes
further indicated that amino acid variation was not uniformly
distributed over the genome-wide open reading frame. The E2
gene was significantly distinguished from the other genes with the
highest amino acid variation in both intra-time-point and inter-
time-point comparisons. Besides, the genes of p7, NS2, NS3 and
NS5B showed significantly higher yearly change of the Shannon
entropy between the early and late time points in the participants
with mild disease outcomes than in those with severe disease
outcomes, suggesting that these four non-structural genes
experienced less efficient purifying selection in the mild disease
cases than in the severe disease cases. The elevated fixation of
slightly deleterious mutations in the non-structural genes might
incur significant disadvantages to the replication of HCV variants,
since these genes have all been shown to play essential roles in the
viral life cycle [42]. Although the outcome of chronic hepatitis C is
heavily influenced by host factors such as age, gender, alcohol
abuse, obesity [43], and possibly host genetics, the enhanced
polymorphism of viral genomes could partially account for the
relatively weakened pathogenesis and slower disease progression in
the participants with mild disease.
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efficient in large populations. Mutations are affected mostly by
random drift when the selection coefficient (s) is less than the
reciprocal of the effective population size (|s|,1/Ne) [44]. In a
population with small effective size, the variants with small
selection coefficients, particularly slightly deleterious mutations,
will act as strictly neutral alleles to drift to higher frequencies and
even to reach fixation [45,46]. In the current study, the viral
population sizes, as shown with the HCV RNA level in serum,
fluctuated over time in the participants with either mild or severe
disease outcomes (Figure 8). The participants with severe
outcomes showed greater variation of viral loads compared to
the mild cases (log10 IU/ml=4.7–7.3 for the severe and 5.6–6.8
for the mild, respectively), and it is notable that the serum
collections from the participants with severe outcomes were
performed all at the peak platform of viral loads, and in the cases
of 1 and 3, years after the viral breakthrough. Overall, the HCV
viral loads were slightly higher in the severe cases compared to the
mild cases (median=6.20 vs. 6.13 respectively) and slightly
increased according to the duration of infection (median=6.03
for the first decade and 6.23 for the following decades).
Interestingly, a previous study at a larger population scale from
the same cohort of Alaska Native persons showed significant
increasing viral loads according to the decades of infection [9].
The study also demonstrated that participants with mild disease
had significantly greater changes in HCV RNA levels between
specimens than did those with severe disease [9]. Since effective
population size is nearer to the lower values than the higher values
in the cases of fluctuating population sizes [37], the viral load data
are consistent with the genetic evidence of more efficient purifying
selection in severe disease.
Recently, bioinformatics and biophysical approaches have been
applied to identify the configurations of viral genomic RNA,
including the genome of HCV, and other mammalian RNA
viruses. HCV showed evidence of genome-scale ordered RNA
structure (GORS), identified as extensive internal base-pairing
throughout the coding sequences, using a bioinformatics approach
[47]. In vitro experiments further confirmed that HCV RNA
transcripts were largely inaccessible to complimentary probes in
hybridization solutions, and were maintained as tightly compacted
structures during the deposition process under atomic force
microscope [48]. Comparison among multiple viral families
indicates that the presence of GORS is strongly associated with
the ability of viral infections to persist in their natural hosts [47].
The maintenance of GORS is therefore an evolutionarily
conserved feature, and hypothetically constrains the neutral drift
of RNA virus sequences. It raises an intriguing possibility that the
selection of synonymous and non-synonymous nucleotide substi-
tutions within the HCV genome is not simply due to amino acid
variation, but also due to nucleotide interactions in the secondary
RNA structure [49], which we did not analyze for the present
study.
In summary, the present study characterized the efficiency of
purifying selection of HCV genomes using a variety of genetic
traits including the nucleotide substitutions, the dN/dS ratio and
the Shannon entropy of amino acid variations during chronic
infection. Our results strongly indicate that the HCV genome
has a significantly higher rate of accumulating synonymous
substitutions relative to non-synonymous substitutions. The
effective population size of the virus infecting an individual host
appears to vary more substantially over time in the participants
with mild disease, which results in an elevated fixation
probability of slightly deleterious mutations due to less efficient
purifying selection in small populations. The accumulation of
deleterious mutations might incur a threat to pathogenesis and
viral persistence. However, there is no correlation between the
viral loads and the progression of liver disease, and direct
evidence has not been available to assess the effect of slightly
deleterious mutations on the biochemical function of the viral
genes. Additional analysis is further needed to evaluate in detail
the role of purifying selection and viral pathogenesis during
chronic HCV infection. Likewise, the breadth of potential
interactions between host and pathogen in this disorder needs
further definition.
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Figure S1 Phylogenetic trees based on the Core se-
quences from the 9 participants (P1–9). Clones 1–3 were
obtained from the serum sample at the early time point of the
corresponding participant, and clones 4–6 were obtained from the
sample at the late time point. Panel A, phylogenetic tree based on
the nucleotide sequences of Core. Panel B, Phylogenetic trees
based on the predicted amino acid sequences of Core. The trees
were constructed with the neighbor-joining method using the
MacVector 9.5.1 software (MacVector Inc, Cary, NC). Reference
sequences with Accession Numbers (1a, 1b, 2a and 2b) are
included as outgroups and to identify the corresponding genotype.
The scale bar indicates that the horizontal branch length
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Figure 8. Fluctuation of serum HCV RNA level during chronic
infection. Archived RNA levels (Log10 IU/mL) were plotted according
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HCV RNA levels in the participants with consistent mild disease. Panel B,
HCV RNA levels in the participants with severe disease outcome.
doi:10.1371/journal.pone.0019562.g008
Genetic Diversity of Hepatitis C Virus
PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e19562Text S1 The review boards that approved this study
and the corresponding dates.
(DOC)
Author Contributions
Conceived and designed the experiments: SL BJM HRR DRG. Performed
the experiments: HL NB SM HD LT-B RM. Analyzed the data: HL ALH.
Wrote the paper: HL ALH DRG.
References
1. WHO (1999) Hepatitis C–global prevalence (update). Wkly Epidemiol Rec 74:
425–427.
2. Seeff LB (1997) Natural history of hepatitis C. Hepatology 26: 21S–28S.
3. McMahon BJ, Bruden D, Bruce MG, Livingston S, Christensen C, et al. (2010)
Adverse outcomes in Alaska natives who recovered from or have chronic
hepatitis C infection. Gastroenterology 138: 922–931 e921.
4. Feld JJ, Hoofnagle JH (2005) Mechanism of action of interferon and ribavirin in
treatment of hepatitis C. Nature 436: 967–972.
5. Kuiken C, Simmonds P (2009) Nomenclature and numbering of the hepatitis C
virus. Methods Mol Biol 510: 33–53.
6. Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus–15 years
on. J Gen Virol 85: 3173–3188.
7. Domingo E, Martin V, Perales C, Grande-Perez A, Garcia-Arriaza J, et al.
(2006) Viruses as quasispecies: biological implications. Curr Top Microbiol
Immunol 299: 51–82.
8. Li H, McMahon BJ, McArdle S, Bruden D, Sullivan DG, et al. (2008) Hepatitis
C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis
C. Virology 375: 580–591.
9. Sullivan DG, Bruden D, Deubner H, McArdle S, Chung M, et al. (2007)
Hepatitis C virus dynamics during natural infection are associated with long-
term histological outcome of chronic hepatitis C disease. J Infect Dis 196:
239–248.
10. Li H, Sullivan DG, Feuerborn N, McArdle S, Bekele K, et al. (2010) Genetic
diversity of hepatitis C virus predicts recurrent disease after liver transplantation.
Virology 402: 248–255.
11. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, et al. (2008)
Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical
outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48:
38–47.
12. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, et al. (1996)
Mutations in the nonstructural protein 5A gene and response to interferon in
patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77–81.
13. Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, et al. (2003) Identification of
a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin
monotherapy. Hepatology 38: 869–878.
14. Wohnsland A, Hofmann WP, Sarrazin C (2007) Viral determinants of resistance
to treatment in patients with hepatitis C. Clin Microbiol Rev 20: 23–38.
15. McMahon BJ, Hennessy TW, Christensen C, Bruden D, Sullivan DG, et al.
(2004) Epidemiology and risk factors for hepatitis C in Alaska Natives.
Hepatology 39: 325–332.
16. Bruce MG, Bruden D, McMahon BJ, Christensen C, Homan C, et al. (2006)
Hepatitis C infection in Alaska Natives with persistently normal, persistently
elevated or fluctuating alanine aminotransferase levels. Liver Int 26: 643–649.
17. Bruce MG, Bruden D, McMahon BJ, Christensen C, Homan C, et al. (2008)
Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients
with chronic hepatitis C. J Viral Hepat 15: 179–187.
18. Davidson F, Simmonds P, Ferguson JC, Jarvis LM, Dow BC, et al. (1995) Survey
of major genotypes and subtypes of hepatitis C virus using RFLP of sequences
amplified from the 59 non-coding region. J Gen Virol 76(Pt 5): 1197–1204.
19. Li H, Thomassen LV, Majid A, McMahon BJ, Bruden D, et al. (2008)
Investigation of putative multisubtype hepatitis C virus infections in vivo by
heteroduplex mobility analysis of core/envelope subgenomes. J Virol 82:
7524–7532.
20. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological
grading and staging of chronic hepatitis. J Hepatol 22: 696–699.
21. Scheuer PJ, Standish RA, Dhillon AP (2002) Scoring of chronic hepatitis. Clin
Liver Dis 6: 335–347, v–vi.
22. Korber B (2000) HIV Signature and Sequence Variation Analysis. In:
Rodrigo AG, Learn GH, eds. Computational Analysis of HIV Molecular
Sequences, Kluwer Academic Publishers, Dordrecht, Netherlands. pp 55–72.
23. Nei M, Gojobori T (1986) Simple methods for estimating the numbers of
synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 3:
418–426.
24. Li WH (1993) Unbiased estimation of the rates of synonymous and
nonsynonymous substitution. J Mol Evol 36: 96–99.
25. Yang Z, Nielsen R (2000) Estimating synonymous and nonsynonymous
substitution rates under realistic evolutionary models. Mol Biol Evol 17: 32–43.
26. Nei M, Kumar S (2000) Molecular evolution and phylogenetics. Oxford
University Press, New York.
27. Korber BT, Kunstman KJ, Patterson BK, Furtado M, McEvilly MM, et al.
(1994) Genetic differences between blood- and brain-derived viral sequences
from human immunodeficiency virus type 1-infected patients: evidence of
conserved elements in the V3 region of the envelope protein of brain-derived
sequences. J Virol 68: 7467–7481.
28. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, et al. (1996) Different
clinical behaviors of acute hepatitis C virus infection are associated with different
vigor of the anti-viral cell-mediated immune response. J Clin Invest 98: 706–714.
29. Shoukry NH, Cawthon AG, Walker CM (2004) Cell-mediated immunity and
the outcome of hepatitis C virus infection. Annu Rev Microbiol 58: 391–424.
30. Bowen DG, Walker CM (2005) Mutational escape from CD8+ T cell immunity:
HCV evolution, from chimpanzees to man. J Exp Med 201: 1709–1714.
31. Thimme R, Lohmann V, Weber F (2006) A target on the move: innate and
adaptive immune escape strategies of hepatitis C virus. Antiviral Res 69:
129–141.
32. Horner SM, Gale M, Jr. (2009) Intracellular innate immune cascades and
interferon defenses that control hepatitis C virus. J Interferon Cytokine Res 29:
489–498.
33. Golden-Mason L, Klarquist J, Wahed AS, Rosen HR (2008) Cutting edge:
programmed death-1 expression is increased on immunocytes in chronic
hepatitis C virus and predicts failure of response to antiviral therapy: race-
dependent differences. J Immunol 180: 3637–3641.
34. Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S,
et al. (2009) Negative immune regulator Tim-3 is overexpressed on T cells in
hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and
CD8+ T cells. J Virol 83: 9122–9130.
35. McMahan RH, Golden-Mason L, Nishimura MI, McMahon BJ, Kemper M,
et al. (2010) Tim-3 expression on PD-1+ HCV-specific human CTLs is
associated with viral persistence, and its blockade restores hepatocyte-directed in
vitro cytotoxicity. J Clin Invest.
36. Rehermann B (1996) Immunopathogenesis of viral hepatitis. Baillieres Clin
Gastroenterol 10: 483–500.
37. Kimura M (1983) The neutral theory of molecular evolution. Cambridge
University Press. Cambridge, the United Kingdom.
38. Pavio N, Battaglia S, Boucreux D, Arnulf B, Sobesky R, et al. (2005) Hepatitis C
virus core variants isolated from liver tumor but not from adjacent non-tumor
tissue interact with Smad3 and inhibit the TGF-beta pathway. Oncogene 24:
6119–6132.
39. Mishima K, Sakamoto N, Sekine-Osajima Y, Nakagawa M, Itsui Y, et al. (2010)
Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants.
Virology 405: 361–369.
40. Joyce MA, Walters KA, Lamb SE, Yeh MM, Zhu LF, et al. (2009) HCV induces
oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-
uPA mice. PLoS Pathog 5: e1000291.
41. Fazollah MR (1994) An introduction to information theory. Dover Publications,
Inc. New York, NY.
42. Suzuki T, Aizaki H, Murakami K, Shoji I, Wakita T (2007) Molecular biology of
hepatitis C virus. J Gastroenterol 42: 411–423.
43. Williams R (2006) Global challenges in liver disease. Hepatology 44: 521–526.
44. Li WH (1978) Maintenance of Genetic Variability under the Joint Effect of
Mutation, Selection and Random Drift. Genetics 90: 349–382.
45. Hughes AL (2008) Near neutrality: leading edge of the neutral theory of
molecular evolution. Ann N Y Acad Sci 1133: 162–179.
46. Ohta T (1976) Role of very slightly deleterious mutations in molecular evolution
and polymorphism. Theor Popul Biol 10: 254–275.
47. Simmonds P, Tuplin A, Evans DJ (2004) Detection of genome-scale ordered
RNA structure (GORS) in genomes of positive-stranded RNA viruses:
Implications for virus evolution and host persistence. Rna 10: 1337–1351.
48. Davis M, Sagan SM, Pezacki JP, Evans DJ, Simmonds P (2008) Bioinformatic
and physical characterizations of genome-scale ordered RNA structure in
mammalian RNA viruses. J Virol 82: 11824–11836.
49. McMullan LK, Grakoui A, Evans MJ, Mihalik K, Puig M, et al. (2007) Evidence
for a functional RNA element in the hepatitis C virus core gene. Proc Natl Acad
Sci U S A 104: 2879–2884.
Genetic Diversity of Hepatitis C Virus
PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e19562